Financial Contrast: AC Immune (ACIU) & Its Rivals

AC Immune (NASDAQ: ACIU) is one of 186 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare AC Immune to related businesses based on the strength of its dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Analyst Recommendations

This is a breakdown of current recommendations for AC Immune and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AC Immune 0 0 1 0 3.00
AC Immune Competitors 556 2480 6723 133 2.65

AC Immune currently has a consensus target price of $18.00, indicating a potential upside of 36.99%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.59%. Given AC Immune’s stronger consensus rating and higher probable upside, analysts plainly believe AC Immune is more favorable than its competitors.

Earnings and Valuation

This table compares AC Immune and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
AC Immune $23.55 million -$7.20 million N/A
AC Immune Competitors $217.40 million -$39.57 million -55.48

AC Immune’s competitors have higher revenue, but lower earnings than AC Immune.

Insider & Institutional Ownership

17.1% of AC Immune shares are owned by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

AC Immune has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500. Comparatively, AC Immune’s competitors have a beta of 1.47, meaning that their average stock price is 47% more volatile than the S&P 500.

Profitability

This table compares AC Immune and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AC Immune N/A N/A N/A
AC Immune Competitors -4,690.20% -479.45% -42.75%

Summary

AC Immune beats its competitors on 8 of the 12 factors compared.

AC Immune Company Profile

AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.